Skip to Content
You are currently on the new version of our website. Access the old version .

41 Results Found

  • Article
  • Open Access
10 Citations
3,435 Views
11 Pages

Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting

  • Serena Zheng,
  • Kanika Gupta,
  • Piyush Goyal,
  • Reiko Nakajima and ,
  • Laure Michaud,
  • Connie Lee Batlevi,
  • Paul A. Hamlin,
  • Steven Horwitz,
  • Anita Kumar and
  • Erel Joffe
  • + 18 authors+ 13 authors

14 March 2023

Recent prospective clinical trial data suggest that patients with Hodgkin’s lymphoma who continue treatment with ABVD, despite failing to attain a complete metabolic response on interim PET (PET2+), may fare better than previously published. We...

(This article belongs to the Special Issue Hodgkin Lymphoma)
  • Article
  • Open Access
476 Views
11 Pages

Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey

  • Derya Demirtas,
  • Elif Suyani,
  • Alper Koc,
  • Bilal Aygun and ,
  • Zeynep Tugba Karabulut,
  • Nurhilal Buyukkurt,
  • Cagatay Unsal and
  • Didar Yanardag Acik
  • + 3 authors+ 0 author

16 July 2026

Objectives: Novel agents such as brentuximab vedotin and anti-PD-1 antibodies, together with PET-adapted intensified strategies, have improved outcomes in advanced-stage classical Hodgkin lymphoma (cHL). However, their applicability remains limited i...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
1,875 Views
12 Pages

Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group

  • Emel Isleyen,
  • Nurcan Alhan,
  • Esra Terzi Demirsoy,
  • Ayfer Geduk and ,
  • Duygu Nurdan Avci,
  • Mahmut Yeral,
  • Ahmet Burhan Ferhanoglu,
  • Ebru Pekguc,
  • Eren Gunduz and
  • Ozgur Mehtap
  • + 47 authors+ 42 authors

26 September 2025

Background: Classical Hodgkin lymphoma (cHL) demonstrates high survival rates with the ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine); however, the use of bleomycin is associated with a significant risk of pulmonary toxicity. The Ris...

(This article belongs to the Special Issue Hematologic Malignancies: Treatment Strategies and Future Challenges)
  • Article
  • Open Access
5 Citations
2,498 Views
14 Pages

Analysis by TeloView® Technology Predicts the Response of Hodgkin’s Lymphoma to First-Line ABVD Therapy

  • Hans Knecht,
  • Nathalie Johnson,
  • Marc N. Bienz,
  • Pierre Brousset and ,
  • Lorenzo Memeo,
  • Yulia Shifrin,
  • Asieh Alikhah,
  • Sherif F. Louis and
  • Sabine Mai
  • + 4 authors+ 0 author

10 August 2024

Classic Hodgkin’s lymphoma (cHL) is a curable cancer with a disease-free survival rate of over 10 years. Over 80% of diagnosed patients respond favorably to first-line chemotherapy, but few biomarkers exist that can predict the 15–20% of...

(This article belongs to the Section Cancer Biomarkers)
  • Article
  • Open Access
6 Citations
3,922 Views
13 Pages

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling

  • Bent Honoré,
  • Maja Dam Andersen,
  • Diani Wilken,
  • Peter Kamper and ,
  • Francesco d’Amore,
  • Stephen Hamilton-Dutoit and
  • Maja Ludvigsen
  • + 2 authors+ 0 author

4 January 2022

In classic Hodgkin lymphoma (cHL), the tumour microenvironment (TME) is of major pathological relevance. The paucity of neoplastic cells makes it important to study the entire TME when searching for prognostic biomarkers. Cure rates in cHL have impro...

(This article belongs to the Special Issue Novel Markers in Lymphoma)
  • Article
  • Open Access
2 Citations
2,726 Views
8 Pages

Impact of Time-to-Treatment Initiation and First Inter-Cycle Delay in Patients with Hodgkin Lymphoma

  • Deniz Donmez,
  • Yasemin Evlendi,
  • Taha Koray Sahin,
  • Ibrahim Barista and
  • Serkan Akin

10 June 2025

Background: Delays in treatments are frequent in real-world lymphoma management. This study evaluates the impact of diagnosis-to-treatment intervals (DTIs) and first inter-cycle delay (IcD) on outcomes in patients with Hodgkin lymphoma (HL) receiving...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
7 Citations
3,419 Views
7 Pages

Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience

  • Ovidiu Potre,
  • Monica Pescaru,
  • Alexandra Sima,
  • Ioana Ionita and ,
  • Raluca Tudor,
  • Ema Borsi,
  • Miruna Samfireag and
  • Cristina Potre
  • + 3 authors+ 0 author

27 September 2021

Background and objectives: Hodgkin lymphoma (HL) is characterized by the presence of malignant Reed Sternberg cells. Although the current curability rate in patients with HL has increased, up to 30% of those in the advanced stages and 5% to 10% of th...

  • Article
  • Open Access
10 Citations
5,716 Views
19 Pages

Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients

  • Theodoros P. Vassilakopoulos,
  • Maria Arapaki,
  • Panagiotis T. Diamantopoulos,
  • Athanasios Liaskas and ,
  • Fotios Panitsas,
  • Marina P. Siakantaris,
  • Maria Dimou,
  • Styliani I. Kokoris,
  • Sotirios Sachanas and
  • Maria K. Angelopoulou
  • + 28 authors+ 23 authors

5 January 2024

The significance of serum beta-2 microglobulin (sβ2m) in Hodgkin lymphoma (HL) is controversial. We analyzed 915 patients with HL, who were treated with ABVD or equivalent regimens with or without radiotherapy. Sβ2m levels were measured by...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
11 Citations
5,116 Views
11 Pages

26 July 2021

Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, whi...

(This article belongs to the Special Issue Hodgkin Lymphoma)
  • Article
  • Open Access
8 Citations
5,969 Views
11 Pages

Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin’s Lymphoma

  • Grace Fangmin Tan,
  • Siting Goh,
  • Esther Wei Yin Chang,
  • Ya Hwee Tan and ,
  • Jianbang Chiang,
  • Valerie Shiwen Yang,
  • Eileen Yi Ling Poon,
  • Nagavalli Somasundaram,
  • Mohamad Farid Bin Harunal Rashid and
  • Jason Yongsheng Chan
  • + 8 authors+ 3 authors

10 February 2023

Hodgkin’s lymphoma carries an excellent prognosis with modern chemotherapy, but a significant proportion of patients remain refractory to or relapse after first-line treatment. Immunological changes post-treatment, such as chemotherapy-induced...

  • Review
  • Open Access
1 Citations
7,407 Views
22 Pages

Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review

  • Vibor Milunović,
  • Ida Hude,
  • Goran Rinčić,
  • Davor Galušić and ,
  • Aron Grubešić,
  • Marko Martinović,
  • Nika Popović,
  • Sunčana Divošević,
  • Klara Brčić and
  • Slobodanka Ostojić Kolonić
  • + 13 authors+ 8 authors

14 November 2022

Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under-represented in phase III trials. Prior to treatment initiatio...

(This article belongs to the Section Molecular and Translational Medicine)
  • Review
  • Open Access
1,061 Views
14 Pages

Systemic Therapy for Advanced-Stage Hodgkin Lymphoma

  • Varun Iyengar,
  • Kishan Patel and
  • Alison Moskowitz

12 June 2026

Advanced-stage classic Hodgkin lymphoma (cHL) represents one of the major success stories in modern oncology, with long-term survival now exceeding 80% for most patients. In this review, we examine the evolution of frontline therapy for advanced-stag...

(This article belongs to the Special Issue Advances in Hodgkin Lymphoma (HL))
  • Article
  • Open Access
12 Citations
3,438 Views
18 Pages

Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy

  • Fazıl Çağrı Hunutlu,
  • Hikmet Öztop,
  • Vildan Gürsoy,
  • Tuba Ersal and ,
  • Ezel Elgün,
  • Şeyma Yavuz,
  • Selin İldemir Ekizoğlu,
  • Azim Ali Ekizoğlu,
  • Vildan Özkocaman and
  • Fahir Özkalemkaş
  • + 5 authors+ 0 author

Background: Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high as 90% using the current treatment protocols, the prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progressio...

(This article belongs to the Special Issue Diagnosis and Management of Hematologic Malignancies)
  • Article
  • Open Access
2 Citations
1,218 Views
18 Pages

Routine Imaging Surveillance After Frontline ABVD Improves Outcome in High-Risk Hodgkin Lymphoma

  • Novella Pugliese,
  • Marco Picardi,
  • Annamaria Vincenzi,
  • Claudia Giordano and ,
  • Anna Lucania,
  • Alessandro Severino,
  • Claudia Salvatore,
  • Massimo Mascolo,
  • Paola Della Cioppa and
  • Fabrizio Pane
  • + 5 authors+ 0 author

6 October 2025

Background/Objectives: Despite the high complete response (CR) rate to first-line therapy, approximately one-third of patients with advanced-stage Hodgkin lymphoma (HL) eventually relapse. In up to 30–50% of cases, relapses are subclinical, i.e...

(This article belongs to the Special Issue Advances in Hodgkin Lymphoma (HL))
  • Article
  • Open Access
10 Citations
3,280 Views
13 Pages

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy

  • Roberto Tamma,
  • Giuseppe Ingravallo,
  • Francesco Gaudio,
  • Antonio d’Amati and ,
  • Pierluigi Masciopinto,
  • Emilio Bellitti,
  • Loredana Lorusso,
  • Tiziana Annese,
  • Vincenzo Benagiano and
  • Domenico Ribatti
  • + 7 authors+ 2 authors

17 May 2023

Although classical Hodgkin lymphoma (CHL) is typically curable, 15–25% of individuals eventually experience a relapse and pass away from their disease. In CHL, the cellular microenvironment is constituted by few percent of H/RS (Hodgkin/Reed&nd...

(This article belongs to the Special Issue The Tumor Microenvironment and Its Role in Tumor Growth and Angiogenesis)
  • Article
  • Open Access
1 Citations
2,538 Views
14 Pages

The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients

  • Dan Fayette,
  • Veronika Juríčková,
  • Iveta Fajnerová,
  • Jiří Horáček and
  • Tomáš Kozák

28 April 2025

Background/Objectives: Cancer- or chemotherapy-related cognitive deficit is a common side effect occurring in patients with Hodgkin lymphoma. No previous study compared the influence of different types of treatment on the onset and development of che...

(This article belongs to the Special Issue Blood Stem Cell and Hematological Malignancies)
  • Article
  • Open Access
5 Citations
4,603 Views
10 Pages

Infertility as a consequence of therapy presents a high psychosocial burden for HL patients. In the cohort of our analyzed patients, within the post-ABVD surviving patients, alterations of the spermogram were documented in a total of 6.1% of the male...

  • Article
  • Open Access
3,353 Views
16 Pages

Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects

  • Shahin Roshani,
  • Flora E. van Leeuwen,
  • Sara Rossetti,
  • Michael Hauptmann and ,
  • Otto Visser,
  • Josée M. Zijlstra,
  • Martin Hutchings,
  • Michael Schaapveld and
  • Berthe M. P. Aleman
  • + 4 authors+ 0 author

24 August 2025

Background/Objectives: There is a need for prediction models which enable weighing benefits against risks of different treatment strategies for individual Hodgkin lymphoma (HL) patients. Therefore, we aimed to predict absolute risk of progression, fi...

(This article belongs to the Special Issue Radiation Therapy in Lymphoma)
  • Article
  • Open Access
2 Citations
1,400 Views
9 Pages

Treatment results of Hodgkin’s lymphoma

  • Eduardas Aleknavičius,
  • Konstantinas Povilas Valuckas,
  • Birutė Aleknavičienė,
  • Laura Norkienė and
  • Giedrė Smailytė

9 August 2009

During last decades, there are strengthening attitudes to optimize the treatment of Hodgkin’s lymphoma considering prognostic groups and risk factors. Based on the data of Vilnius University Clinics, a retrospective study was carried out, and treatme...

  • Protocol
  • Open Access
1 Citations
655 Views
16 Pages

Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial Protocol

  • Kateryna Filonenko,
  • Marco Picardi,
  • Stephane Chauvie,
  • Andrea Riccardo Filippi and ,
  • Maria Cristina Pirosa,
  • Luca Guerra,
  • Federico Fallanca,
  • Marta Bednarek,
  • Michał Kurlapski and
  • Jan Maciej Zaucha
  • + 17 authors+ 12 authors

Radiation-free treatment for early-stage classic Hodgkin lymphoma (eHL) has been shown to be less effective than standard combined-modality treatment (CMT; chemotherapy plus involved-node radiotherapy (INRT)), which achieves long-term disease control...

(This article belongs to the Section Immunology and Immunotherapy)
  • Article
  • Open Access
3 Citations
2,418 Views
12 Pages

Myocardial Metabolic Response Predicts Chemotherapy Curative Potential on Hodgkin Lymphoma: A Proof-of-Concept Study

  • Cecilia Marini,
  • Matteo Bauckneht,
  • Anna Borra,
  • Rita Lai and ,
  • Maria Isabella Donegani,
  • Alberto Miceli,
  • Cristina Campi,
  • Vanessa Cossu,
  • Daniela Schenone and
  • Gianmario Sambuceti
  • + 9 authors+ 4 authors

Genome sharing between cancer and normal tissues might imply a similar susceptibility to chemotherapy toxicity. The present study aimed to investigate whether curative potential of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is predic...

(This article belongs to the Section Immunology and Immunotherapy)
  • Article
  • Open Access
1 Citations
1,197 Views
17 Pages

Unclassified Chromosomal Abnormalities as an Indicator of Genomic Damage in Survivors of Hodgkin’s Lymphoma

  • Sandra Ramos,
  • Bertha Molina,
  • María del Pilar Navarrete-Meneses,
  • David E. Cervantes-Barragan and ,
  • Valentín Lozano and
  • Sara Frias
  • + 1 author+ 0 author

23 July 2025

Background/Objectives: Hodgkin’s lymphoma (HL) affects 2–4 individuals per 100,000 annually. Standard treatment includes radiotherapy and ABVD chemotherapy, achieving a 95% survival rate. However, HL survivors face an elevated risk of tre...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
1 Citations
1,263 Views
14 Pages

The Impact of Radiotherapy and Attenuated Chemotherapy Regimens in Older Patients with Classic Hodgkin Lymphoma: A Real-Life Study from the ReLLi Network

  • Maria Christina Cox,
  • Matteo Caridi,
  • Alexandro Patirelis,
  • Ilaria Del Giudice and ,
  • Alessandro Pulsoni,
  • Daniela Renzi,
  • Sabrina Pelliccia,
  • Roberta Battistini,
  • Paola Anticoli Borza and
  • Luigi Rigacci
  • + 20 authors+ 15 authors

24 February 2025

Background/Objectives: The treatment of older patients with classic Hodgkin lymphoma (eHL) remains a challenge. Methods: This study reports the first real-life survey of eHL treated with contemporary therapies in Italy. One hundred and fifty eHL pati...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
1 Citations
6,965 Views
9 Pages

12 September 2024

Background: Some cases of classic Hodgkin lymphoma (CHL) display similarities to nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) in terms of architecture, leading to potential challenges in diagnosis. However, these difficulties can be overco...

(This article belongs to the Collection Lymphomas)
  • Review
  • Open Access
14 Citations
6,773 Views
28 Pages

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

  • Theodoros P. Vassilakopoulos,
  • Athanasios Liaskas,
  • Patricio Pereyra,
  • Panayiotis Panayiotidis and ,
  • Maria K. Angelopoulou and
  • Andrea Gallamini
  • + 1 author+ 0 author

24 August 2023

The long-term survival of Hodgkin lymphoma (HL) patients treated according to the current standard of care is excellent. Combined-modality schedules (ABVD plus radiotherapy) in early-stage disease, along with treatment intensity adaptation to early m...

(This article belongs to the Section Molecular Immunology)
  • Systematic Review
  • Open Access
3 Citations
2,538 Views
35 Pages

Hodgkin Lymphoma—The Effect of Chemotherapy on Gonadal Function and Fertility Is Strongly Related to the Treatment Regimen, Age, and Sex: A Systematic Review and Meta-Analysis

  • Mareike Roth-Hochreutener,
  • Maria Karakitsiou,
  • Angela Vidal,
  • Susanna Weidlinger and ,
  • Janna Pape,
  • Tanya Karrer,
  • Karolin Behringer and
  • Michael von Wolff
  • + 3 authors+ 0 author

28 January 2026

Background/Objectives: Hodgkin lymphoma (HL) primarily affects individuals of reproductive age, making gonadal dysfunction after chemotherapy a critical survivorship concern. While fertility preservation options including gamete and gonadal tissue cr...

(This article belongs to the Section Systematic Review or Meta-Analysis in Cancer Research)
  • Article
  • Open Access
7 Citations
3,728 Views
10 Pages

Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment

  • Elizabeth Katherine Anna Triumbari,
  • David Morland,
  • Annarosa Cuccaro,
  • Elena Maiolo and ,
  • Stefan Hohaus and
  • Salvatore Annunziata
  • + 1 author+ 0 author

26 September 2022

(1) This study aimed to investigate whether baseline clinical and Positron Emission Tomography/Computed Tomography (bPET)-derived parameters could help predicting early response to the first two cycles of chemotherapy (Deauville Score at interim PET,...

(This article belongs to the Section Machine Learning and Artificial Intelligence in Diagnostics)
  • Article
  • Open Access
10 Citations
5,455 Views
14 Pages

Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up

  • Novella Pugliese,
  • Marco Picardi,
  • Roberta Della Pepa,
  • Claudia Giordano and ,
  • Francesco Muriano,
  • Aldo Leone,
  • Giuseppe Delle Cave,
  • Alessandro D’Ambrosio,
  • Violetta Marafioti and
  • Fabrizio Pane
  • + 8 authors+ 3 authors

7 April 2021

Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare variant of HL that accounts for 5% of all HL cases. The expression of CD20 on neoplastic lymphocytes provides a suitable target for novel treatments based on Rituximab. Due...

(This article belongs to the Section Molecular Cancer Biology)
  • Review
  • Open Access
28 Citations
5,918 Views
22 Pages

Nonclonal Chromosome Aberrations and Genome Chaos in Somatic and Germ Cells from Patients and Survivors of Hodgkin Lymphoma

  • Sara Frias,
  • Sandra Ramos,
  • Consuelo Salas,
  • Bertha Molina and ,
  • Silvia Sánchez and
  • Roberto Rivera-Luna
  • + 1 author+ 0 author

10 January 2019

Anticancer regimens for Hodgkin lymphoma (HL) patients include highly genotoxic drugs that have been very successful in killing tumor cells and providing a 90% disease-free survival at five years. However, some of these treatments do not have a speci...

(This article belongs to the Special Issue Chromosomal Heterogeneity and Human Diseases)
  • Case Report
  • Open Access
1 Citations
2,796 Views
9 Pages

Complications of Brentuximab Therapy in Patients with Hodgkin’s Lymphoma and Concurrent Autoimmune Pathology—A Case Series

  • Oana Diana Preda,
  • Sorina Bădeliță,
  • Iulia Ursuleac,
  • Ruxandra Maria Irimia and ,
  • Sonia Balanica,
  • Monica Cojocaru,
  • Cristina Cotruta,
  • Camelia Dobrea and
  • Daniel Coriu
  • + 4 authors+ 0 author

Background: Brentuximab Vedotin (BV) has revolutionized the treatment landscape for Hodgkin’s lymphoma, yet its effects on pre-existing autoimmune disorders remain elusive. Methods: Here, we present four cases of patients with concurrent autoim...

  • Review
  • Open Access
3 Citations
3,209 Views
13 Pages

Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review

  • Vittorio Ruggero Zilioli,
  • Cristina Muzi,
  • Chiara Pagani,
  • Emanuele Ravano and ,
  • Erika Meli,
  • Rosa Daffini,
  • Erika Ravelli,
  • Roberto Cairoli and
  • Alessandro Re
  • + 4 authors+ 0 author

28 February 2023

Along with the fact that classical Hodgkin lymphoma (cHL) in older adults is frequently considered biologically different from cHL in younger patients, its most distinctive feature is its dismal clinical outcome due to the decreased effectiveness and...

(This article belongs to the Special Issue Recent Research of Geriatric Hematology)
  • Article
  • Open Access
2 Citations
1,938 Views
11 Pages

The Application of Existing Risk Assessment Models (RAMS) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin Lymphoma

  • Mohammad Ma’koseh,
  • Alaa Abufara,
  • Dana Albaghdadi,
  • Ruba Ghalayni and ,
  • Sarah Abdel-Razeq,
  • Eman Alzughali,
  • Fadwa Abdel Rahman,
  • Yazan Alhalaseh,
  • Khalid Halahleh and
  • Hikmat Abdel-Razeq
  • + 5 authors+ 0 author

12 January 2024

Background: A majority of patients included in risk assessment models (RAMs) developed to predict venous thromboembolic events (VTE) in lymphoma were non-Hodgkin lymphoma. Our study aims to evaluate the incidence and predictors of VTE, utilizing diff...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
9 Citations
2,859 Views
15 Pages

Reduction of the Vertebral Bone Mineral Density in Patients with Hodgkin Lymphoma Correlates with Their Age and the Treatment Regimen They Received

  • Nadav Ofshenko,
  • Eyal Bercovich,
  • Tania Mashiach,
  • Michal Weiler-Sagie and ,
  • Daniela Militianu and
  • Eldad J. Dann
  • + 1 author+ 0 author

19 January 2022

Nowadays, Hodgkin lymphoma (HL) has become highly curable. The young age at diagnosis and long life expectancy emphasize the importance of preventing long-term treatment side effects, including bone mineral density (BMD) loss, in these patients. We a...

(This article belongs to the Section Cancer Therapy)
  • Case Report
  • Open Access
617 Views
8 Pages

Ophelia syndrome is a rare paraneoplastic limbic encephalitis associated with classical Hodgkin lymphoma (cHL), most often with antibodies against metabotropic glutamate receptor 5 (mGluR5). We describe a 19-year-old man with newly diagnosed cHL who...

(This article belongs to the Special Issue Treatment and Prognosis of Hematological Malignancies)
  • Article
  • Open Access
7 Citations
3,916 Views
19 Pages

Predicting Hospitalization in Older Adults Using Machine Learning

  • Raymundo Buenrostro-Mariscal,
  • Osval A. Montesinos-López and
  • Cesar Gonzalez-Gonzalez

Background/Objectives: Hospitalization among older adults is a growing challenge in Mexico due to the high prevalence of chronic diseases and limited public healthcare resources. This study aims to develop a predictive model for hospitalization using...

  • Case Report
  • Open Access
920 Views
11 Pages

Synchronous Breast and Kidney Carcinomas Following Treatment for Hodgkin’s Lymphoma in Young Adulthood: A Case Report and Literature Review

  • Milan Žegarac,
  • Milan Kocić,
  • Dobrica Stević,
  • Anđelija Cvetković and ,
  • Ognjen Živković,
  • Anđela Milićević,
  • Marko Buta,
  • Ivan Marković,
  • Igor Đurišić and
  • Zorka Inić
  • + 6 authors+ 1 author

10 December 2025

Background/Objectives: Multiple primary malignancies (MPMs) are defined as the occurrence of two or more independent primary tumors in the same patient, histologically distinct and not of metastatic origin. Patients treated for Hodgkin’s lympho...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
11 Citations
3,425 Views
14 Pages

Prognostic Role of the Expression of Latent-Membrane Protein 1 of Epstein–Barr Virus in Classical Hodgkin Lymphoma

  • Antonio Santisteban-Espejo,
  • Jose Perez-Requena,
  • Lidia Atienza-Cuevas,
  • Julia Moran-Sanchez and ,
  • Maria del Carmen Fernandez-Valle,
  • Irene Bernal-Florindo,
  • Raquel Romero-Garcia and
  • Marcial Garcia-Rojo
  • + 3 authors+ 0 author

15 December 2021

The prognostic impact of the presence of Epstein–Barr virus (EBV) in classical Hodgkin lymphoma (cHL) is controversial. Previous studies reported heterogeneous results, rendering difficult the clinical validation of EBV as a prognostic biomarker in t...

(This article belongs to the Special Issue Recent Progress in Tumor Virology Research)
  • Review
  • Open Access
1,505 Views
18 Pages

29 June 2026

Classical Hodgkin lymphoma (cHL) remains one of the most curable hematologic malignancies, with long-term survival exceeding 80–90% in most contemporary series. However, a subset of patients experience primary refractory disease, relapse, treat...

(This article belongs to the Special Issue Therapeutic Advances in Hematological Malignancies: New Breakthroughs and Future Directions)
  • Article
  • Open Access
2 Citations
3,848 Views
16 Pages

Impact of Comorbidities on Prognosis and Treatment Outcomes in Elderly Patients with Hodgkin Lymphoma

  • Dávid Tóthfalusi,
  • Boglárka Dobó,
  • Fanni Borics,
  • László Imre Pinczés and ,
  • Árpád Illés and
  • Zsófia Miltényi
  • + 1 author+ 0 author

Background/Objectives: Hodgkin lymphoma (HL) primarily affects young adults, but about 20% of cases occur in patients over the age of 60 years. Older individuals often have comorbidities and poorer functional status, which can affect treatment choice...

  • Systematic Review
  • Open Access
15 Citations
7,113 Views
29 Pages

Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi

  • Luca Nassi,
  • Vitaliana De Sanctis,
  • Giacomo Loseto,
  • Chiara Gerardi and ,
  • Eleonora Allocati,
  • Sabino Ciavarella,
  • Carla Minoia,
  • Attilio Guarini and
  • Alessia Bari
  • + 4 authors+ 0 author

20 January 2022

Background: The increase of lymphoma patient survival led to a modification of the incidence of long-term sequelae, including second malignancies (SM). Several groups have dealt with the incidence of SM, according to the primary treatment; however, a...

(This article belongs to the Special Issue Lymphoma Survivorship)
  • Article
  • Open Access
1 Citations
480 Views
12 Pages

Glasgow Prognostic Score and Gustave Roussy Immune Score in Hodgkin Lymphoma: Survival Associations and Limited Incremental Prognostic Value Beyond the International Prognostic Score

  • Kemal Aygün,
  • Şerife Solmaz,
  • Olgu Aygün,
  • İbrahim Eryılmaz and ,
  • Tugba Cetintepe,
  • Hatice Demet Kiper Unal,
  • Alev Garip Acar and
  • Eray Arslan
  • + 3 authors+ 0 author

2 July 2026

Background/Objectives: Although outcomes in Hodgkin lymphoma (HL) have improved substantially, patients with advanced-stage disease, comorbidities, or relapsed/refractory presentations can still fare poorly. Blood-based indices of systemic inflammati...

(This article belongs to the Special Issue Hematologic Malignancies: Treatment Strategies and Future Challenges: 2nd Edition)